Japan Regulator Begins Five-Year Program Of Drug-Approval Reforms
This article was originally published in PharmAsia News
Japan's Pharmaceuticals and Medical Devices Agency has kicked off a five-year program aimed at reducing the time it takes to get a drug to market. The plan also is intended to step up the country's participation in worldwide clinical trials, an increasing trend in the pharmaceutical industry. PMDA also has a pilot program consisting of a scientific consultation for companies to use before they submit applications for approval of new drugs. The pre-review consultation is designed to occur during Phase III trials. (Click here for more
You may also be interested in...
TOKYO - The number of clinical trials being performed in Japan is trending upward every year, but trial costs fluctuate sharply from year to year, according to survey results released by Japan's Pharmaceutical Manufacturers Association
In a 1 June speech before the Alliance For a Stronger FDA, US FDA commissioner Stephen Hahn stressed the agency’s vigilance in guarding against consumer use of flawed COVID-19 products. He also made comments about the need for doctors to communicate more with patients. See what he said about the use of telehealth here.
Request for documents and a briefing is part of efforts to ensure federal programs are ‘protected from price gouging.’